Investment Rating - The investment rating for the company is "Buy" [4] Core Views - The company is expected to see rapid growth in adjusted profits in 2024, with business development (BD) achievements highlighting its innovative capabilities, leading to potential valuation increases [1][2] - The company reported a revenue of 6.635 billion RMB in 2024, a year-over-year increase of 0.4%, and an adjusted net profit of approximately 1.018 billion RMB, reflecting a year-over-year growth of 41.6% [1][2] - The innovative drug segment is projected to continue its upward trend, with revenues from innovative drugs reaching 4.928 billion RMB in 2024, accounting for 74.3% of total revenue [2] Summary by Sections Performance - In 2024, the company achieved a group revenue of 6.635 billion RMB and a net profit of 733 million RMB, with an adjusted net profit of approximately 1.018 billion RMB [1] - The company has made significant progress with multiple innovative drugs, including the approval of two new drugs and the acceptance of three new drug NDAs [1] Innovation - The revenue from innovative drugs is expected to grow, driven by existing products and new launches, maintaining a high growth rate [2] - The partnership with AbbVie for the licensing of a new candidate drug demonstrates the strength of the company's innovation platform [2] Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025-2027 is projected to be 0.43, 0.55, and 0.63 RMB, respectively, with a price-to-earnings (P/E) ratio of 19 times based on the closing price on April 24, 2025 [3] - The company is expected to maintain rapid growth in performance driven by both existing and new innovative drug products [3]
先声药业（02096）：点评：主业利润高增，创新持续验证